Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
Abstract Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine treatment efficacy, safety, and tolerability is limi...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/85e212b2b1294997a15ab3ee23884b36 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:85e212b2b1294997a15ab3ee23884b36 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:85e212b2b1294997a15ab3ee23884b362021-11-28T12:36:34ZEfficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies10.1186/s10194-021-01351-21129-23691129-2377https://doaj.org/article/85e212b2b1294997a15ab3ee23884b362021-11-01T00:00:00Zhttps://doi.org/10.1186/s10194-021-01351-2https://doaj.org/toc/1129-2369https://doaj.org/toc/1129-2377Abstract Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine treatment efficacy, safety, and tolerability is limited in this population. We evaluated efficacy, safety, and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene–related peptide (CGRP), in clinical trial participants aged ≥60 years with episodic migraine (EM) or chronic migraine (CM). Methods This analysis included data from 3 randomized, double-blind, placebo-controlled phase 3 studies: the HALO EM study, HALO CM study, and FOCUS study in participants with EM or CM and prior inadequate response to 2–4 migraine preventive medication classes. Participants in all studies were randomized 1:1:1 to receive 12 weeks of subcutaneous treatment with quarterly fremanezumab (Months 1/2/3: EM/CM, 675 mg/placebo/placebo), monthly fremanezumab (Months 1/2/3: EM, 225 mg/225 mg/225 mg; CM, 675 mg/225 mg/225 mg), or matched monthly placebo. Results These pooled analyses included 246 participants aged ≥60 years. Reductions in monthly migraine days from baseline over 12 weeks were significantly greater with fremanezumab (least-squares mean change from baseline [standard error]: quarterly fremanezumab, − 4.3 [0.59]; monthly fremanezumab, − 4.6 [0.54]) versus placebo (placebo, − 2.3 [0.57]; both P < 0.01 vs placebo). As early as Week 1, significant reductions from baseline in weekly migraine days were observed with fremanezumab versus placebo (both P < 0.01). With fremanezumab treatment versus placebo, a significantly higher proportion of participants achieved ≥50% reduction in monthly migraine days, and significant improvements in disability and quality-of-life outcomes were observed (P < 0.05). Proportions of participants experiencing serious adverse events and adverse events leading to discontinuation were low and similar in the fremanezumab and placebo groups. Efficacy and safety results were comparable to the overall pooled population (N = 2843). Conclusions This pooled subgroup analysis demonstrates that fremanezumab treatment is efficacious and well-tolerated over 12 weeks in participants aged ≥60 years with EM or CM. These data may help healthcare providers with clinical decision making and preventive treatment selection for older patients with migraine. Trial registration ClinicalTrials.gov identifiers: HALO CM: NCT02621931 ; HALO EM: NCT02629861 ; FOCUS: NCT03308968 .Stephanie J. NahasSteffen NaegelJoshua M. CohenXiaoping NingLindsay JankaVerena Ramirez CamposLynda J. KrasenbaumDagny Holle-LeeDavid KudrowChristian LamplBMCarticleEpisodic migraineChronic migraineFremanezumabCGRPOlder ageMedicineRENThe Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Episodic migraine Chronic migraine Fremanezumab CGRP Older age Medicine R |
| spellingShingle |
Episodic migraine Chronic migraine Fremanezumab CGRP Older age Medicine R Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| description |
Abstract Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evidence for migraine treatment efficacy, safety, and tolerability is limited in this population. We evaluated efficacy, safety, and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene–related peptide (CGRP), in clinical trial participants aged ≥60 years with episodic migraine (EM) or chronic migraine (CM). Methods This analysis included data from 3 randomized, double-blind, placebo-controlled phase 3 studies: the HALO EM study, HALO CM study, and FOCUS study in participants with EM or CM and prior inadequate response to 2–4 migraine preventive medication classes. Participants in all studies were randomized 1:1:1 to receive 12 weeks of subcutaneous treatment with quarterly fremanezumab (Months 1/2/3: EM/CM, 675 mg/placebo/placebo), monthly fremanezumab (Months 1/2/3: EM, 225 mg/225 mg/225 mg; CM, 675 mg/225 mg/225 mg), or matched monthly placebo. Results These pooled analyses included 246 participants aged ≥60 years. Reductions in monthly migraine days from baseline over 12 weeks were significantly greater with fremanezumab (least-squares mean change from baseline [standard error]: quarterly fremanezumab, − 4.3 [0.59]; monthly fremanezumab, − 4.6 [0.54]) versus placebo (placebo, − 2.3 [0.57]; both P < 0.01 vs placebo). As early as Week 1, significant reductions from baseline in weekly migraine days were observed with fremanezumab versus placebo (both P < 0.01). With fremanezumab treatment versus placebo, a significantly higher proportion of participants achieved ≥50% reduction in monthly migraine days, and significant improvements in disability and quality-of-life outcomes were observed (P < 0.05). Proportions of participants experiencing serious adverse events and adverse events leading to discontinuation were low and similar in the fremanezumab and placebo groups. Efficacy and safety results were comparable to the overall pooled population (N = 2843). Conclusions This pooled subgroup analysis demonstrates that fremanezumab treatment is efficacious and well-tolerated over 12 weeks in participants aged ≥60 years with EM or CM. These data may help healthcare providers with clinical decision making and preventive treatment selection for older patients with migraine. Trial registration ClinicalTrials.gov identifiers: HALO CM: NCT02621931 ; HALO EM: NCT02629861 ; FOCUS: NCT03308968 . |
| format |
article |
| author |
Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl |
| author_facet |
Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl |
| author_sort |
Stephanie J. Nahas |
| title |
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_short |
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full |
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_fullStr |
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full_unstemmed |
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_sort |
efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| publisher |
BMC |
| publishDate |
2021 |
| url |
https://doaj.org/article/85e212b2b1294997a15ab3ee23884b36 |
| work_keys_str_mv |
AT stephaniejnahas efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT steffennaegel efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT joshuamcohen efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT xiaopingning efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT lindsayjanka efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT verenaramirezcampos efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT lyndajkrasenbaum efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT dagnyhollelee efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT davidkudrow efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT christianlampl efficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies |
| _version_ |
1718407901143367680 |